부산대학교 도서관

>=10 cm palpable splenomegaly was present in 23.8% of patients in an overall cohort and 13.2% early PMF, 30.7% overt PMF, 35.1% post-PV SMF and 14.7% post-ET SMF patients ( I p i = 0.009). Patients presenting with non-palpable in comparison to palpable splenomegaly (HR = 0.53, I p i = 0.008) and patients with 1-9 cm in comparison to >=10 cm palpable splenomegaly (HR = 0.58, I p i = 0.041) experienced significantly better survival. Palpable splenomegaly was present in 68.3% of patients in an overall cohort and 54.3% early PMF, 76.8% overt PMF, 87.9% post-PV SMF and 53.1% post-ET SMF patients ( I p i = 0.003). Splenomegaly is a hallmark of primary (PMF) and secondary myelofibrosis (SMF), developing mostly due to extramedullary hematopoiesis [[1]]. [Extracted from the article]